Anti-CD19 antibody drug conjugate

JP7844719B2Active Publication Date: 2026-04-13ABBVIE BIOTHERAPEUTICS INC
-1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
ABBVIE BIOTHERAPEUTICS INC
Filing Date
2025-07-02
Publication Date
2026-04-13

Smart Images

  • Figure 0007844719000029
    Figure 0007844719000029
  • Figure 0007844719000030
    Figure 0007844719000030
  • Figure 0007844719000031
    Figure 0007844719000031
Patent Text Reader

Abstract

To provide an agent that delivers a glucocorticoid modulator to treat diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL).SOLUTION: The present invention provides antibody-drug conjugates that target B-cells via an anti-CD19 antibody linked to a glucocorticoid receptor modulator (GRM) agonist payload.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art